![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Clover Biopharmaceuticals Ends COVID-19 Vaccine Pact With GlaxoSmithKline
Clover Biopharmaceuticals Ends COVID-19 Vaccine Pact With GlaxoSmithKline
China’s Clover Biopharmaceuticals has ended its partnership with UK-based GlaxoSmithKline (GSK) that aimed to develop a COVID-19 vaccine using GSK’s adjuvant technology.
Instead, Clover is collaborating with Dynavax Technologies and launching a global phase 2/3 trial to assess the efficacy of its S-Trimer vaccine candidate combined with a Dynavax adjuvant.
In December, GSK and Sanofi announced they would delay a phase 2b trial of their adjuvanted COVID-19 vaccine candidate after it produced an insufficient immune response in older patients.
Upcoming Events
-
21Oct